NCT06346067 2026-02-27A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)Erasca, Inc.Phase 3 Active not recruiting78 enrolled
NCT03907488 2025-12-04Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin LymphomaNational Cancer Institute (NCI)Phase 3 Active not recruiting994 enrolled 11 charts